Ocular FIP treatment gains traction as antiviral evidence grows
CURRENT BRIEF VERSION: A new VetGirl podcast is spotlighting a fast-moving area of feline medicine: treatment of ocular feline infectious peritonitis, or FIP, with antiviral drugs, especially GS-441524 and remdesivir. The discussion centers on a 2025 Royal Veterinary College case series and lands amid a broader shift in FIP care, as evidence continues to build that antivirals can improve outcomes even in more complicated presentations, including cats with ocular signs, though these cases often need higher dosing and closer follow-up than uncomplicated effusive disease. The podcast also underscores a practical point for clinicians: ocular disease may be the first clue to FIP, with findings such as uveitis, keratic precipitates, iris color change, dyscoria, hyphema, retinal lesions, hemorrhage, or detachment. In the U.S., access also changed materially in 2024, when FDA said it did not intend to enforce approval requirements for patient-specific compounded GS-441524 prescribed by veterinarians under certain conditions, and compounded oral GS-441524 became available through U.S. pharmacy channels soon after. (fda.gov)
Why it matters: For veterinary professionals, ocular FIP is no longer automatically a hopeless diagnosis, but it remains a management challenge. Published data and guideline summaries suggest cats with ocular or neurologic signs generally require higher antiviral doses than cats with uncomplicated effusive FIP, and response monitoring matters because systemic improvement can precede full ophthalmic improvement. That caution also fits with newer discussion around refining FIP protocols more broadly: some clinicians are exploring whether high-dose induction and objective stopping criteria such as acute-phase proteins and albumin:globulin trends could eventually help tailor duration, but the literature still supports extra caution in cats with eye or CNS involvement because those tissues are harder to penetrate. Evidence reviews also suggest overall GS-441524 success rates are high, while more complicated cases still carry a lower margin for error and may need dose adjustment, longer treatment, or combination strategies if response is incomplete. (pubmed.ncbi.nlm.nih.gov)
What to watch: Expect continued debate over optimal dosing, treatment duration, and when ocular FIP cases should move to higher-dose or combination antiviral protocols. Also watch how clinicians integrate practical diagnostic cues, since FIP remains largely a presumptive diagnosis in real practice and early recognition of compatible signalment, inflammatory eye disease, effusion, hyperglobulinemia, or other systemic clues still shapes treatment decisions. (abcdcatsvets.org)